The Research Desk
Growth hormone output declines with age, and two peptides, CJC-1295 and Ipamorelin, are commonly stacked in research settings to probe that decline through two different receptor pathways. The pivotal human trial behind CJC-1295, however, tested a longer-acting molecular variant than the one most research catalogues, including Helix's, actually list, a distinction worth stating plainly before looking at what the data shows.
What CJC-1295 and Ipamorelin are
Growth hormone (GH) secretion is governed by two opposing hypothalamic signals: growth hormone-releasing hormone (GHRH), which stimulates release, and somatostatin, which suppresses it. Both CJC-1295 and Ipamorelin were developed as synthetic tools to act on this axis without administering GH itself.
CJC-1295 is a synthetic analog of GHRH. Native GHRH has a plasma half-life of only a few minutes, which limits its research utility. The molecule studied by Teichman and colleagues incorporated a Drug Affinity Complex (DAC), a modification that binds circulating albumin and extends the compound's half-life from minutes to days (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006). A separate, unmodified variant of the same peptide sequence, commonly labelled "CJC-1295 No DAC" or Mod GRF (1-29), lacks this albumin-binding modification and clears the body far faster. These are pharmacologically distinct research articles, and the distinction matters: the multi-day GH elevation reported by Teichman et al. was measured with the DAC-modified molecule. Helix's catalogue lists the No DAC variant, blended with Ipamorelin, and that formulation has not been evaluated in the same trial.
Ipamorelin is a five-amino-acid peptide belonging to a separate class, the growth hormone secretagogues, which act at the growth hormone secretagogue receptor (GHSR) rather than the GHRH receptor. It was originally developed in the 1990s as part of a broader research effort to find selective, non-GHRH ways of triggering pituitary GH release.
Mechanism of action, in preclinical and early pharmacology research
CJC-1295 has been studied for its potential role in sustaining elevated plasma GH concentrations by prolonging GHRH receptor stimulation. In the Teichman et al. trial, a single injection of the DAC-modified molecule in healthy adults aged 21 to 61 was associated with mean GH concentrations increasing 2 to 10-fold, sustained for 6 days or more, alongside IGF-1 increases of 26 to 86% sustained for up to 14 days (Teichman et al., 2006).
Ipamorelin's proposed mechanism is receptor-level selectivity: it is described in the pharmacology literature as a ghrelin-receptor mimetic that triggers pulsatile GH release without the same degree of cortisol or prolactin co-release reported for older, less selective secretagogues. This is a mechanistic description rather than a demonstrated clinical outcome, and Helix has not identified a verified, peer-reviewed human trial isolating Ipamorelin's effect in the way the Teichman study isolates CJC-1295 with DAC. That gap is treated as a limitation below rather than filled with unverified sourcing.
The rationale for combining the two compounds in a research context rests on their engaging separate receptors, GHRH receptor for CJC-1295 and GHSR for Ipamorelin, which is proposed to produce an additive rather than redundant signal. Whether that additive effect has been measured directly, as opposed to inferred from the two mechanisms independently, is not established by a verified source at the time of writing.
Where the human evidence on CJC-1295 and Ipamorelin stands
The strongest human data available is the Teichman et al. 2006 dose-escalation study, a randomized, placebo-controlled, double-blind trial in healthy adults. It measured single-injection pharmacodynamics of GH and IGF-1 for the DAC-modified form of CJC-1295. It did not test the No DAC variant, did not test Ipamorelin, and did not test the two compounds in combination. No verified trial in Helix's source list has evaluated the CJC-1295 No DAC plus Ipamorelin blend as a combined intervention in humans.
The honest summary: One well-controlled human trial supports a pharmacodynamic effect of DAC-modified CJC-1295 on GH and IGF-1 levels over days. That trial does not describe the shorter-acting No DAC variant that Helix and most research suppliers list, and no verified human trial in this review evaluates Ipamorelin alone or the CJC-1295 No DAC / Ipamorelin combination. The receptor mechanisms are well established in pharmacology; the combined, human, No DAC-specific evidence is thin. Treat the two as separate evidentiary claims, not one.
Regulatory context
Neither CJC-1295 nor Ipamorelin is approved by the FDA or any equivalent regulator for human therapeutic use outside of specific, distinct growth-hormone-deficiency indications governed by different approved drugs. Both compounds are included on the WADA Prohibited List for competitive sport. Within the Helix catalogue, CJC-1295 No DAC and Ipamorelin are listed strictly for research use.
The bottom line
The GHRH and GHSR mechanisms underlying CJC-1295 and Ipamorelin are well characterized at the receptor level, and one human trial documents a sustained GH and IGF-1 response to the DAC-modified form of CJC-1295. What remains studied rather than established is whether the No DAC variant, listed in most research catalogues, reproduces that same magnitude and duration of effect, and whether combining it with Ipamorelin adds a measured, rather than inferred, effect in humans. Researchers working with either compound should treat catalogue-variant labelling as a first-order question, not a footnote.
Frequently asked questions
What is CJC-1295?
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). The version tested in the pivotal 2006 human trial included a Drug Affinity Complex (DAC) modification that extends its half-life to several days. A separate, unmodified variant, commonly called CJC-1295 No DAC, clears much faster and is pharmacologically distinct. It is supplied for research use only.
What does Ipamorelin research focus on?
Ipamorelin has been studied for its potential role in triggering pulsatile growth hormone release through the growth hormone secretagogue receptor (GHSR), with a proposed selectivity profile that limits cortisol and prolactin co-release compared with older secretagogues. Verified, peer-reviewed human trial data isolating this effect is limited.
Is the combination safe or does it have human data?
The most robust human data available, the Teichman et al. 2006 trial, evaluated DAC-modified CJC-1295 alone, not the No DAC variant, not Ipamorelin, and not the combination. Reported side effects for GH secretagogues in the broader literature are generally described as mild, including water retention, headache, and flushing, but this article does not assert a safety profile for the combined blend beyond what has been directly studied.
How does this compare to a repair-focused peptide like BPC-157?
CJC-1295 and Ipamorelin target the growth hormone axis through GHRH and GHSR receptors, with the strongest single data point being a 2006 human pharmacodynamic trial. BPC-157 research instead centers on angiogenesis and repair-related pathways, largely in preclinical models, with very limited early-stage human pilot data. See the Helix Research Desk review of BPC-157 for that evidence base.
CJC-1295 No DAC and Ipamorelin are listed in the Helix catalogue as a blend, for research use only: view the product page. Mechanism background is available on the Helix Science page.